Under construction – not a live service
Sign in
Taking people in ChinaPhase 4

Tirofiban With Blood-Thinning Pills for Mild Stroke

Tests tirofiban with blood-thinning pills in adults with mild acute ischemic stroke.

Key facts

Who runs it
Second Affiliated Hospital of Soochow University
Where
Bayan Nur, Huai'an, Shijiazhuang, Suqian, Suzhou, Taizhou, Tianjin, Xi'an, Xianyang, and Zhoukou, ChinaSee the 18 sites
Trial code
Registry title
Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke
Status
Recruiting
Phase
Phase 4
People taking part
580 people, planned
Started
30 Aug 2025
Expected to end
31 May 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tirofiban+Oral Dual Antiplatelet Therapy
  • Oral Dual Antiplatelet Therapy
Record updated
31 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-80 who have had a mild stroke that was not caused by a heart clot, and can start the study drug within 48 hours of the first symptoms.

Age
18-80 years
Sex
All sexes can join.
Disease stage
Acute mild stroke not caused by a clot from the heart (non-cardioembolic), with an NIHSS score of 5 or less. Randomization within 48 hours of onset.
Earlier treatment
People who have had or are planned to have intravenous thrombolysis or bridging therapy cannot join. Treatment with direct oral anticoagulants in the previous 48 hours is also not allowed.

Main reasons for not taking part

  • Bleeding in the brain seen on imaging, or a history of brain bleeding
  • Any confirmed heart source of clots, such as atrial fibrillation
  • Serious bleeding within 30 days, or major surgery within 14 days
  • Platelet count below 100 × 10⁹/L, or severe kidney problems
  • Current pregnancy or breastfeeding

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Age: 18-80 years old
  • Acute mild non-cardioembolic stroke
  • NIHSS score ≤5
  • Time from onset to randomization of ≤48 hours; if the time of onset is unknown, time from the last known time of being well to randomization of ≤48 hours
  • The investigational drug can be administered within 48 hours of symptom onset
  • Signed informed consent by the patient or legally authorized representative

Who cannot take part

  • Received or planned to receive intravenous thrombolysis or bridging therapy (with subsequent endovascular treatment)
  • Major surgery within 14 days
  • Intracranial hemorrhage confirmed by imaging
  • Pre-stroke modified Rankin Scale (mRS) score ≥2
  • History of primary intracerebral hemorrhage
  • History of other intracranial hemorrhage (intraventricular, subarachnoid, epidural, or subdural hemorrhage)
  • Major systemic bleeding within 30 days
  • Known allergy or contraindication to tirofiban or aspirin
  • Any terminal illness with life expectancy <6 months
  • Any confirmed cardioembolic source, including chronic or paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, infective endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction <30%
  • Active bleeding, including laboratory evidence of coagulopathy (platelet count <100 × 10⁹/L, activated partial thromboplastin time >50 seconds, or international normalized ratio >1.7), or treatment with direct oral anticoagulants within the preceding 48 hours
  • Baseline platelet count <100 × 10⁹/L
  • Severe renal dysfunction (glomerular filtration rate <30 mL/min or serum creatinine >220 μmol/L [2.5 mg/dL])
  • Untreated or inadequately treated intracranial aneurysm or vascular malformation
  • Persistently elevated blood pressure (systolic >180 mmHg or diastolic >110 mmHg) despite treatment
  • Current pregnancy or lactation
  • Any intracranial tumor (except asymptomatic meningiomas ≤1.5 cm in diameter)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in China

  • WuYuan County People's HospitalBayan Nur, ChinaContact: Yongming ChenTaking people
  • Huai'an First People's HospitalHuai'an, ChinaContact: Kun AnTaking people
  • Second Hospital of Hebei Medical UniversityShijiazhuang, ChinaContact: Zichun ZhaoTaking people
  • Jiangsu Province （Suqian）HospitalSuqian, ChinaContact: Dan LiTaking people
  • Affiliated Jiangsu Shengze Hospital of Nanjing Medical UniversitySuzhou, ChinaContact: Shenglong WangTaking people
  • Changshu No.1 People's HospitalSuzhou, ChinaContact: Taosheng LuTaking people
  • First People's Hospital of KunshanSuzhou, ChinaContact: Guihua MiaoTaking people
  • Second Affiliated Hospital of Soochow UniversitySuzhou, ChinaContact: Jijun Shi, M.DTaking people
  • Suzhou Municipal Hospital of Anhui ProvinceSuzhou, ChinaContact: Yingzhi LiangTaking people
  • Suzhou Ninth People's HospitalSuzhou, ChinaContact: Guojie ZhaiTaking people
  • Suzhou Xiangcheng People's HospitalSuzhou, ChinaContact: Xiaoyun HanTaking people
  • Taicang TCM Hospital Affiliated to Nanjing University of Chinese MedicineSuzhou, ChinaContact: Jijun Shi, M.DTaking people
  • Zhangjiagang Hospital of Traditional Chinese MedicineSuzhou, ChinaContact: Yaming SunTaking people
  • Taixing Second People's HospitalTaizhou, ChinaContact: Ligong JiTaking people
  • Second Hospital of Tianjin Medical UniversityTianjin, ChinaContact: Dongliang WangTaking people
  • Nuclear Industry 417 HospitalXi'an, ChinaContact: Tao XuTaking people
  • First People's Hospital of XianyangXianyang, ChinaContact: Yugang WangTaking people
  • Taikang Xian People's HospitalZhoukou, ChinaContact: Haiyang ShuTaking people

About the trial

What the trial wants to find out

This study aims to evaluate whether initiating intravenous tirofiban within 48 hours of onset (with a 48-hour infusion), followed by sequential DAPT, can improve the likelihood of excellent functional outcomes (modified Rankin Scale score 0-1) in mild stroke patients, compared with standard DAPT therapy based on current guidelines.

The 2 groups in the trial

  • Tirofiban+Oral Dual Antiplatelet TherapyTreatment being tested

    Patients will receive tirofiban in the first 48 hours and then be switched to oral dual antiplatelet therapy thereafter

  • oral dual antiplatelet therapyExisting treatment, for comparison

    Patients will receive oral dual antiplatelet therapy alone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Tirofiban With Sequential Dual Antiplatelet Therapy Versus Dual Antiplatelet Therapy Alone in Mild Acute Ischemic Stroke (TiMIS): A Multicenter, Open-Label, Blinded-Endpoint, Parallel-Controlled, Randomized Clinical Trial
Plain-language title
Tirofiban With Blood-Thinning Pills for Mild StrokeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07095790, who can take part
Publications
Record updated
31 July 2025